Compare ADMA Biologics Inc (ADMA) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs KKR & Co Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while KKR & Co Inc trades at $93.3 (market cap $85.42B). The key difference: KKR & Co Inc is far larger — about 40.1× ADMA Biologics Inc's market cap, and KKR & Co Inc pays a 0.79% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KKR | |
|---|---|---|
Market Cap | $2.13B | $85.42B |
Sector | Health | Financials |
52-Week High | $20.38 | $152.16 |
52-Week Low | $7.60 | $83.88 |
Enterprise Value | $2.20B | $10.95B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
KKR trades at $95.14, up 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows strong analyst sentiment with 24 buy ratings and a consensus price target of $127.43. Recent developments include a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, highlighting strategic growth initiatives. Financials reveal a P/E of 32.64 and net income margin of 14.51%, with Q1 2026 EPS beating expectations at $1.39 versus $1.26 estimated.
The outlook for KKR is positive, driven by expansion in renewable energy and private credit leadership, though risks include integration challenges from acquisitions and market volatility. Earnings growth and strategic deals present upside potential, with the current price offering a 34% discount to the analyst target. Investors should monitor Q2 2026 results due July 30, 2026, for further catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
